To perform a systematic review and meta-analysis of all randomized controlled trials comparing efficacy of Intermittent versus continuous chemotherapy (CT) for first-line treatment of unresectable Metastatic Colorectal Cancer (CCRm). METHODS: Several databases were searched, including MEDLINE, EM-BASE, LILACS, and CENTRAL. The primary endpoint was overall survival (OS). The data extracted from the studies were combined by using Hazard Ratio (HR) with their corresponding 95% confidence intervals (CI95%). RESULTS: Overall, 733 references were identified and screened. The final analysis included 4 trials comprising 1,827 patients analyzed. There was no statistically significant difference between the groups (Intermittent vs continuous chemotherapy) on the analysis of overall survival (fixed effect: HRϭ1.03, CI95%ϭ0.92 to 1.16; pϭ0.56). No heterogeneity was detected on this analysis (Chi2 ϭ 2.88, df ϭ 3 (Pϭ0.41); I2 ϭ 0%). CONCLUSIONS: Overall survival was similar between groups. The intermittent chemotherapy regimen provides better quality of life that the scheme is continued and probably cost saving. (cervix, vulva, vagina, anus, penis and HϩN) and grouped according to ICD-O-3 site. Incidence rates were age-adjusted (ASR) to the European standard population by the direct method and 95% Confidence intervals (95% CI) calculated using STATA SE11.0. A literature review was conducted to ascertain the percentage attributable to HPV for each cancer type. Over 300 articles were reviewed and graded by relevance, sample size, and date. RESULTS: ASRs for HPV-related cancers were: vagina/ vulval cancers: 0.33(95% CI 0.3-0.4) and 1.4(95% CI: 1.3-1.4) per 100,000 females. Penile cancer: 0.8(95% CI: 0.7-0.8) per 100,000 males. Anal cancers: 10.8(95% CI:10.7-11.1) males and 6.0(95% CI:5.8-6.0) females per 100,000. Base of tongue and lingual tonsil: 0.06(95% CI:0.06-0.07) males and 0.02(95% CI:0.01-0.02) females per 100,000; tonsil: 0.11(95% CI:0.10-0.12) males and 0.03(95% CI:0.03-0.04) females per 100,000; oropharynx: 0.05(95% CI:0.05-0.06) males and 0.02(95% CI:0.01-0.02) females per 100,000. Estimates reported in literature for percentage of HPV-attributable cases ranged from 70-100% for cervical, 27-76% vulval, 70-90% vaginal, 40-54% penile, 76-90% anal, and 11-72% for HPV-associated HϩN cancers. The most commonly reported strains were HPV 16, 18, 31, and 33. CONCLUSIONS: The incidence of HPV-related cancers represents a significant burden. Recent incidence estimates are similar to 2002 estimates, apart from an increase in anal cancers. Estimates of the HPV-attributable percentage for each cancer and projected prevalence will be used to assess the impact of implementing a quadrivalent HPV vaccination programme in England. OBJECTIVES: Metastatic bone lesions lead to an increase in the risk for skeletal related events (SREs), including pathologic fracture, spinal cord compression, hypercalcemia of malignancy, and severe bone pain requiring palliative radiotherapy or surgery to bone. Twenty-nine percent of breast cancer patients with bone metastases develop SREs. Our objective was to systematically review the literature on the impact of SREs on pain, quality of life (QOL), morbidity, survival and cost in breast cancer patients. METHODS: We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on a SRE definition accepted by the U.S. Food and Drug Administration and European Medicines Agency. Articles were included if they were randomized-controlled trials, clinical trials with appropriate control group, systematic reviews, meta-analyses, case-series or economic analyses, and were excluded if they did not provide interpretable results on outcomes of interest. RESULTS: A total of 209 articles were screened, of which 131 were excluded, and 78 were abstracted. No studies, outside of bisphosphonate trials, were identified that examined the impact of SREs as a group on clinical outcomes. Bisphosphonate treatment reduced SREs, and hence improved pain and QOL. Literature indicated that presence of pathologic bone fractures is correlated with increased risk of death. Spinal cord compression significantly impaired ambulatory function and shortened survival of these patients compared to historical controls. Radiation therapy improved pain and QOL while bone surgery was shown to improve pain and function with vertebrectomy. Limited evidence suggested treatment cost of SREs is $14,000 (95% CI: $11,000-$17,000) per patient. CONCLUSIONS: Presence of clinical SREs is associated with worse morbidity and survival, while their treatment is associated with improved pain, QOL and morbidity among breast cancer patients. SREs appear to increase cost of treatment substantially. 
PCN20 SYSTEMATIC REVIEW OF SKELETAL RELATED EVENTS IN BREAST CANCER
OBJECTIVES: Metastatic bone lesions lead to an increase in the risk for skeletal related events (SREs), including pathologic fracture, spinal cord compression, hypercalcemia of malignancy, and severe bone pain requiring palliative radiotherapy or surgery to bone. Twenty-nine percent of breast cancer patients with bone metastases develop SREs. Our objective was to systematically review the literature on the impact of SREs on pain, quality of life (QOL), morbidity, survival and cost in breast cancer patients. METHODS: We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on a SRE definition accepted by the U.S. Food and Drug Administration and European Medicines Agency. Articles were included if they were randomized-controlled trials, clinical trials with appropriate control group, systematic reviews, meta-analyses, case-series or economic analyses, and were excluded if they did not provide interpretable results on outcomes of interest. RESULTS: A total of 209 articles were screened, of which 131 were excluded, and 78 were abstracted. No studies, outside of bisphosphonate trials, were identified that examined the impact of SREs as a group on clinical outcomes. Bisphosphonate treatment reduced SREs, and hence improved pain and QOL. Literature indicated that presence of pathologic bone fractures is correlated with increased risk of death. Spinal cord compression significantly impaired ambulatory function and shortened survival of these patients compared to historical controls. Radiation therapy improved pain and QOL while bone surgery was shown to improve pain and function with vertebrectomy. Limited evidence suggested treatment cost of SREs is $14,000 (95% CI: $11,000-$17,000) per patient. CONCLUSIONS: Presence of clinical SREs is associated with worse morbidity and survival, while their treatment is associated with improved pain, QOL and morbidity among breast cancer patients. SREs appear to increase cost of treatment substantially. 
PCN21 SYSTEMATIC REVIEW OF SKELETAL RELATED EVENTS IN PROSTATE CANCER

OBJECTIVES:
Between 65-75% of patients with prostate cancer experience metastatic bone disease. Metastatic bone lesions increase risk for skeletal related events (SREs), which include clinical SREs (pathologic fracture, spinal cord compression, hypercalcemia of malignancy) and treatments of clinical SREs (radiotherapy or surgery to bone) resulting from severe bone pain. Our objective was to systematically review the literature on the impact of SREs on pain, quality of life (QOL), morbidity, survival and cost in prostate cancer patients. METHODS: We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on SRE definition accepted by the US Food and Drug Administration and European Medicines Agency. Articles were included if they were randomized-controlled trials, clinical trials with appropriate control group, systematic reviews, meta-analyses, case-series or economic analyses, and were excluded if they did not provide interpretable results on outcomes of interest. RESULTS: A total of 209 articles were screened, of which 131 were excluded, and 78 were abstracted. No studies, outside of bisphosphonate trials, were identified that examined the impact of SREs as a group on clinical outcomes. In bisphosphonate trials, patients with SREs had significantly more pain and worse 1-year survival compared with no SREs. Pathologic bone fractures significantly decreased QOL and were associated with increased risk of death. Although spinal cord compression (SCC) has a significant impact on pain, improvement in morbidity may be achieved if SCC is treated. SCC is associated with significant decreases in patient survival. Radiation therapy improved pain and possibly QOL while bone surgery improved pain. Limited evidence suggested SREs increased cost by approximately €7,000 (Euros) and $12,000 (USD). CONCLUSIONS: Clinical SREs are associated with worse clinical outcomes, including pain, QOL, morbidity and survival, while treatment of clinical SREs is associated with improved pain and QOL among prostate cancer patients. SREs appear to increase cost substantially.
PCN22 SAFETY PROFILE OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER
